In the preceding three months, 12 analysts have released ratings for Vertex (NASDAQ:VERX), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll find a ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

During the last three months, 9 analysts shared their evaluations of Vertex (NASDAQ:VERX), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below ...

Vertex Pharmaceuticals (VRTX ... At the same time, the Dow lost 0.07%, and the tech-heavy Nasdaq lost 0.9%. Shares of the drugmaker witnessed a loss of 14.25% over the previous month, trailing ...

Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (LSE:0A3L) from Outperform to Market Perform. There are 474 funds or institutions reporting positions in ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...

Raymond James downgraded Vertex (VERX) to Market Perform from Outperform without a price target The firm repositioned several ratings throughout the application software sector at the start of 2025.

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

DA Davidson analyst William Jellison initiated coverage of Vertex (VERX) with a Buy rating and $62 price target Vertex “exhibits several characteristics exemplifying sustained value-capture and ...

That's what recently happened to Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech company. Here is why now is as good a time as any to "buy low" when it comes to this stock. Vertex Pharmaceuticals ...

Vertex Pharmaceuticals (VRTX ... Elsewhere, the Dow gained 0.91%, while the tech-heavy Nasdaq added 1.35%. The the stock of drugmaker has fallen by 12.22% in the past month, lagging the Medical ...